Total Funding
42
44
Total FundingPost-IPO Equity raised
Growth Score 42 in past quarter
-20 pts
Heat Score 44 in past quarter
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
34445
Intensity Therapeutics is a biopharmaceutical company that provides chemotherapy treatment for cancer patients.
- Lewis Bender: Founder and CEO
- Joseph Talamo: Chief Financial OfficerPast Role: HiberCell, Senior Vice President and Chief Financial Officer
About the Company
Intensity Therapeutics, Inc., a biopharmaceutical company, provides chemotherapy treatments for cancer patients. It engages in the direct intratumoral injection of novel pharmaceutical formulations for cancer administration. Intensity Therapeutics, Inc. was incorporated in 2012 and is based in Norwalk, Connecticut.
